Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 946-584-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 July to 09 August 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- GLP study conducted in compliance with OECD Guideline No. 429 without any deviation.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Version / remarks:
- adopted 22 July 2010
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay)
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- UK GLP Compliance Programme (inspected on July 05, 2016/ signed on October 28, 2016)
- Type of study:
- mouse local lymph node assay (LLNA)
Test material
- Reference substance name:
- Resinoid of Canarium luzonicum (Burseraceae) obtained from the exudate by cyclohexane extraction
- EC Number:
- 946-584-9
- Molecular formula:
- Not applicable (UVCB)
- IUPAC Name:
- Resinoid of Canarium luzonicum (Burseraceae) obtained from the exudate by cyclohexane extraction
- Test material form:
- other: Pale yellow to dark yellow paste
- Details on test material:
- Substance type: UVCB (Natural Complex Substance)
Name: Elemi resinoid
Test substance storage: Dry area, unopened containers, optimum temp. 11-25°C.
Purpose of testing: REACH
Date of expiration: 17 May 2021
Constituent 1
- Specific details on test material used for the study:
- Identification: Elemi RDE INDE
Batch: 1003395243
Purity: 100% UVCB
Physical state/Appearance: yellow paste
Expiry Date: 17 May 2021
Storage Conditions: room temperature in the dark
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- CBA/Ca
- Remarks:
- CBA/CaOlaHsd
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS B.V., Inc., Horst, The Netherlands.
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: 8-12 weeks
- Weight at study initiation: 15-23 g
- Housing: Animals were housed in suspended solid floor polypropylene cages furnished with softwood woodflakes.
- Diet: Food (2014C Teklad Global Rodent diet supplied by Envigo RMS (UK) Limited, Oxon, UK), ad libitum
- Water: Mains tap water, ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 19-25 °C
- Humidity: 30-70 %
- Air changes: at least 15 changes per hour
- Photoperiod: 12 hours continuous light and 12 hours darkness
Study design: in vivo (LLNA)
- Vehicle:
- other: Butanone
- Concentration:
- 25%, 10% or 5% w/w
- No. of animals per dose:
- 5
- Details on study design:
- PRE-SCREEN TESTS:
- Test Item preparation: For the purpose of the study, the test item was freshly prepared as a solution in butanone. This vehicle was chosen as it produced the highest concentration that was suitable for dosing. The test item was formulated within 2 hours of being applied to the test system. It is assumed that the formulation was stable for this duration.
- Preliminary Screening Test: As no toxicological information was available regarding the systemic toxicity/irritancy potential of the test item, a preliminary screening test was performed using one mouse. The mouse was treated by daily application of 25 μL of the test item at a maximum attainable concentration of 25% w/w in butanone, to the dorsal surface of each ear for three consecutive days (Days 1, 2, 3). The mouse was observed twice daily on Days 1, 2 and 3 and once daily on Days 4, 5 and 6. Local skin irritation was scored daily. Any clinical signs of toxicity, if present, were also recorded. The body weight of the mouse was recorded on Day 1 (prior to dosing) and on Day 6.
The thickness of each ear was measured using a Mitutoyo 547-300S gauge (Mitutoyo Corporation), pre-dose and post dose on Day 1, post dose on Days 2 and 3 and on Days 4, 5 and 6. Any changes in the ear thickness were noted. Mean ear thickness changes were calculated between time periods Days 1 and 3 and Days 1 and 6. A mean ear thickness increase of equal to or greater than 25% was considered to indicate excessive irritation and limited biological relevance to the endpoint of sensitization.
Following the Day 6 ear thickness measurements, the mouse was killed by carbon dioxide asphyxiation followed by cervical separation.
- Results: Fur loss was noted on Days 2 to 6 at a concentration of 25% w/w in butanone.
No signs of systemic toxicity, visual local skin irritation or irritation indicated by an equal to or greater than 25% increase in mean ear thickness were noted.
Based on this information, and after consultation with the Sponsor, the dose levels selected for the main test were 25%, 10% and 5% w/w in butanone.
MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Local Lymph Node Assay, individual method
- Criteria used to consider a positive response: The test item will be regarded as a sensitizer if at least one concentration of the test item results in a threefold or greater increase in 3HTdR incorporation compared to control values. Any test item failing to produce a threefold or greater increase in 3HTdR incorporation will be classified as a "non sensitizer".
TREATMENT PREPARATION AND ADMINISTRATION:
The mice were treated by daily application of 25 μL of the appropriate concentration of the test item to the dorsal surface of each ear for three consecutive days (Days 1, 2, 3). The test item formulation was administered using an automatic micropipette and spread over the dorsal surface of the ear using the tip of the pipette.
A further group of five mice received the vehicle alone in the same manner.
The positive control animals were similarly treated to the test animals except that 25 μL of the positive control item, α-Hexylcinnamaldehyde, tech., 85%, at a concentration of 15% v/v in butanone was applied to the dorsal surface of each ear.
Local skin irritation was scored daily. The thickness of each ear was measured and recorded pre and post dose on Day 1, post dose on Days 2 and 3 and on Days 4, 5 and 6.
Five days following the first topical application of the test item, vehicle control item or positive control item (Day 6) all mice were injected via the tail vein with 250 µL of phosphate buffered saline (PBS) containing 3H methyl thymidine (3HTdR: 80 µCi/mL, specific activity 2.0 Ci/mmoL, ARC UK Ltd) giving a total of 20 µCi to each mouse.
Termination: Five hours following the administration of 3HTdR all mice were killed by carbon dioxide asphyxiation followed by cervical separation. For each individual animal of each group the draining auricular lymph nodes were excised and processed. For each individual animal 1 mL of PBS was added to the lymph nodes.
Preparation of Single Cell Suspension: A single cell suspension of the lymph node cells for each individual animal was prepared by gentle mechanical disaggregation through a 200 mesh stainless steel gauze. The lymph node cells were rinsed through the gauze with 4 mL of PBS into a petri dish labeled with the study number and dose concentration. The lymph node cells suspension was transferred to a centrifuge tube. The petri dish was washed with an additional 5 mL of PBS to remove all remaining lymph node cells and these were added to the centrifuge tube. The lymph node cells were pelleted at 1400 rpm (approximately 190 g) for 10 minutes. The pellet was re suspended in 10 mL of PBS and re pelleted. To precipitate out the radioactive material, the pellet was re suspended in 3 mL of 5% Trichloroacetic acid (TCA).
Determination of 3HTdR Incorporation: AAfter approximately 18 hours incubation at approximately 4 °C, the precipitates were recovered by centrifugation at 2100 rpm (approximately 450 g) for 10 minutes, re suspended in 1 mL of TCA and transferred to 10 mL of scintillation fluid. 3HTdR incorporation was measured by beta scintillation counting. The "Poly Q™" vials containing the samples and scintillation fluid were placed in the sample changer of the scintillator and left to stand in darkness for approximately 20 minutes. The purpose of this period of time in darkness was to reduce the risk of luminescence, which has been shown to affect the reliability of the results. After approximately 20 minutes, the vials were shaken vigorously. The number of radioactive disintegrations per minute was then measured using the Beckman LS6500 scintillation system (Beckman Instruments Inc, Fullerton, CA, USA). - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- Data was processed to give group mean values for disintegrations per minute and standard deviations where appropriate. Individual and group mean disintegrations per minute values were assessed for dose response relationships. Data was first assessed for suitability by analysis of normality and homogeneity of variance. If the assumptions that the data are both normally distributed and has homogeneity of variances, then parametric one way analysis of variance (ANOVA) and Dunnett’s multiple comparison procedure were used to determine statistical significance. If the assumptions were not met, non parametric Kruskal Wallis Rank Sum and Mann Whitney U test procedures were used.
Results and discussion
- Positive control results:
- The positive control α Hexylcinnamaldehyde, tech., 85% gave a Stimulation Index of greater than 3 (5.58) when tested at a concentration of 15% v/v in butanone, thus, demonstrating the sensitivity and reliability of the test system.
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- SI
- Value:
- 1.74
- Test group / Remarks:
- 5% w/w in butanone
- Key result
- Parameter:
- SI
- Value:
- 2.83
- Test group / Remarks:
- 10% w/w in butanone
- Key result
- Parameter:
- SI
- Value:
- 7.1
- Test group / Remarks:
- 25% w/w in butanone
- Key result
- Parameter:
- EC3
- Remarks:
- %
- Value:
- 11
- Cellular proliferation data / Observations:
- CELLULAR PROLIFERATION DATA:
See Table 7.4.1/1 below.
DETAILS ON STIMULATION INDEX CALCULATION
Stimulation index for 5, 10 and 25% w/w in butanone were 1.74, 2.83 and 7.10, respectively.
EC3 CALCULATION
EC3 = c + [[(3-d)/(bd)] x (a-c)]
a=25
b=7.10
c=10
d=2.83
EC3 = 10 + [[(3-2.83)/(7.10-2.83)] x (25-10)] = 11
The concentration of test item expected to cause a 3 fold increase in 3HTdR incorporation (EC3 value) was calculated to be 11%.
CLINICAL OBSERVATIONS: Fur loss was noted on Days 2 (pre-dose) to 6 in animals treated with the test item at a concentration of 25% w/w in butanone.
There were no deaths. No signs of systemic toxicity were noted in the test or control animals during the test (See Table 7.4.2 & 7.4.3 below).
EAR THICKNESS: A greater than 25% increase in mean ear thickness was noted on Days 5 and 6 in the animals treated with the test item at a concentration of 25% w/w in butanone.
BODY WEIGHTS: Body weight change of the test animals between Day 1 and Day 6 was comparable to that observed in the corresponding control group animals over the same period.
Any other information on results incl. tables
Table 7.4.1/1: Individual Disintegrations per Minute and Stimulation Index
Treatment Group |
Animal Number |
dpm/ |
Mean dpm/Animal |
Stimulation Indexb |
Result |
Vehicle |
1-1 |
1457.43 |
1604.50 |
na |
na |
1-2 |
1428.87 |
||||
1-3 |
1708.51 |
||||
1-4 |
1546.41 |
||||
1-5 |
1881.27 |
||||
Test Item |
2-1 |
2154.75 |
2791.94** |
1.74 |
Negative |
2-2 |
2734.47 |
||||
2-3 |
3175.21 |
||||
2-4 |
2751.90 |
||||
2-5 |
3143.36 |
||||
Test Item |
3-1 |
4818.60 |
4542.04** |
2.83 |
Negative |
3-2 |
3290.54 |
||||
3-3 |
3005.84 |
||||
3-4 |
6716.67 |
||||
3-5 |
4878.56 |
||||
Test Item |
4-1 |
10280.66 |
11394.01** |
7.10 |
Positive |
4-2 |
9925.78 |
||||
4-3 |
11420.29 |
||||
4-4 |
12918.62 |
||||
4-5 |
12424.70 |
||||
Positive Control Item |
5-1 |
9625.87 |
8948.65** |
5.58 |
Positive |
5-2 |
6570.26 |
||||
5-3 |
11282.45 |
||||
5-4 |
8753.23 |
||||
5-5 |
8511.44 |
dpm= Disintegrations per minute
a= Total number of lymph nodes per animal is 2
b= Stimulation Index of 3.0 or greater indicates a positive result
**= Significantly different from vehicle control group p<0.01
Table 7.4.1/2: Individual Clinical Observations and Mortality Data
Treatment Group |
Animal Number |
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
|||
Pre-Dose |
Post Dose |
Pre-Dose |
Post Dose |
Pre-Dose |
Post Dose |
|||||
Vehicle |
1-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Test Item |
2-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Test Item |
3-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Test Item |
4-1 |
0 |
0 |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
4-2 |
0 |
0 |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
|
4-3 |
0 |
0 |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
|
4-4 |
0 |
0 |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
|
4-5 |
0 |
0 |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
0Fl |
|
Positive Control Item |
5-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0= No signs of systemic toxicity
Fl = Fur loss was noted
Table 7.4.1/3: Local Skin Irritation
Treatment Group |
Animal Number |
Local Skin Irritation |
|||||||||||
Day 1 |
Day 2 |
Day 3 |
Day 4 |
Day 5 |
Day 6 |
||||||||
left |
right |
left |
right |
left |
right |
left |
right |
left |
right |
left |
right |
||
Vehicle |
1-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Test Item |
2-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
2-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Test Item |
3-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Test Item |
4-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
Positive Control Item |
5-1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
5-2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5-3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5-4 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
5-5 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Applicant's summary and conclusion
- Interpretation of results:
- Category 1B (indication of skin sensitising potential) based on GHS criteria
- Conclusions:
- Under the test conditions, test material is classified as a contact sensitizer (Category 1B) according to Regulation (EC) No. 1272/2008.
- Executive summary:
A study was performed to assess the skin sensitisation potential of test material in the CBA/Ca strain mouse following topical application to the dorsal surface of the ear. The method was conducted according to the OECD test guideline No 429 and in compliance with GLP.
Following a preliminary screening test in which no clinical signs of toxicity or excessive local irritation were noted at a maximum attainable concentration of 25% w/w, this concentration was selected as the highest dose investigated in the main test of the Local Lymph Node Assay. Three groups, each of five animals, were treated with 50 μL (25 μL per ear) of the test item as a solution in butanone at concentrations of 25%, 10% or 5% w/w. A further group of five animals was treated with butanone alone. A concurrent positive control test, using a group of five animals, was also performed with the known sensitizer, α-Hexylcinnamaldehyde tech., 85%, at a concentration of 15% v/v in butanone.
A greater than 25% increase in mean ear thickness was noted on Days 5 and 6 in the animals treated with the test item at a concentration of 25% w/w in butanone.
The proliferative response of the lymph node cells (LNC) from the draining auricular lymph nodes was assessed five days following the initial application, by measurement of the incorporation of 3H-methyl Thymidine (3HTdR) by β-scintillation counting of LNC suspensions. The response was expressed as radioactive disintegrations per minute per lymph node (dpm/node) and as the ratio of 3HTdR incorporation into LNC of test nodes relative to that recorded for control nodes (test/control ratio), termed as Stimulation Index (SI).
Stimulation index for 25%, 10% or 5% w/w in butanone were 7.10, 2.83 and 1.74, respectively. The concentration of test item expected to cause a 3 fold increase in 3HTdR incorporation (extrapolated EC3value) was calculated to be 11%. No sign of systemic toxicity or excessive local skin irritation were noted at the concentrations of 25%, 10% or 5% w/w.
The positive control α-Hexylcinnamaldehyde, tech., 85% gave a Stimulation Index of greater than 3 (5.58) when tested at a concentration of 15% w/w in butanone, thus, demonstrating the sensitivity and reliability of the test system.
Under the test conditions, the test material is classified as a contact sensitizer (Category 1B) according to Regulation (EC) No. 1272/2008.
This study is considered as acceptable and satisfies the requirement for sensitisation endpoint.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)